Hudson, a subsidiary of Hainan Haiyao, independently researched and developed new compounds and obtained US patent

Data show that MDM2 inhibitors are a new type of MDM2 inhibitors with high affinity The new compounds reactivate protein p53 by blocking the interaction between MDM2 and p53 P53 is a precise regulatory factor in human body, also known as "tumor killing shadow", and it is a guard to maintain the integrity of cell genes Almost all cancers are related to the loss of p53 function MDM2 inhibitors is a significant breakthrough in the treatment of cancer, and has a broad application prospect in the treatment of cancer, retinal macular degeneration and other diseases related to p53 The company said that if the product is officially put into production, it needs to go through preclinical research, apply for clinical approval from the FDA, enter into clinical experiments, and according to the results of clinical experiments, the FDA will give the drug production approval before it can be put on the market According to the analysis of market participants, if the company obtains the FDA production approval for listing and sales, according to the U.S market standard, the annual sales volume is at least 1 billion dollars, with a broad prospect Hudson biomedical Co., Ltd (USA), registered in New Jersey science and Technology Park, is mainly engaged in the research of original drugs, improvement of current product process and guidance of chemical synthesis, collection of international pharmaceutical market information and research market dynamics, and prospective research on products, technology and market.